---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335200"
form_type: "8-K"
ticker: "BTMD"
cik: "0001819253"
company_name: "biote Corp."
filed_at: "2026-08-05T20:20:16+00:00"
generated_at: "2026-08-05T20:21:11.632506+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biote Q2 2026 revenue $44.2M (-9.5% YoY); net loss $(7.4)M vs net income $3.9M; updates full-year outlook

## Summary
- Revenue $44.2M (-9.5% YoY); procedure revenue $30.3M (-13.9%) due to voluntary recall of Asteria Health pellets.
- Net loss $(7.4)M ($0.23 diluted loss per share) vs net income $3.9M ($0.10 EPS) in Q2 2025.
- Adjusted EBITDA $5.6M (12.6% margin); gross margin 65.4% vs 71.6% due to recall costs.
- Dietary supplements revenue grew 5.7% to $11.4M.
- Company updated full-year 2026 outlook; specifics not provided in excerpt.

## SEC filing metadata
- accession: 0001193125-26-335200
- form_type: 8-K
- ticker: BTMD
- cik: 0001819253
- company_name: biote Corp.
- filed_at: 2026-08-05T20:20:16+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819253/000119312526335200/0001193125-26-335200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819253/000119312526335200/btmd-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335200
- JSON: https://secwatch.observer/filing/0001193125-26-335200.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.